Tryvio (aprocitentan tablets - Idorsia) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has tried, or is currently receiving, at least three other antihypertensive agents for the treatment of hypertension from at least three of the following pharmacological classes: (i) angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); (ii) non-dihydropyridine calcium channel blocker; (iii) dihydropyridine calcium channel blocker; (iv) diuretic; (v) mineralocorticoid receptor antagonist; (vi) beta blocker; (vii) alpha-adrenergic blocker; (viii) central alpha-adrenergic agonist; (ix) direct vasodilator; (x) direct renin inhibitor

Approval duration

1 year